Search

Home > New FDA Approvals > 110 – Enzalutamide for non-metastatic CRPC; Cellvizio clearance; FDA’s new pilot program aims for more transparency
Podcast: New FDA Approvals
Episode:

110 – Enzalutamide for non-metastatic CRPC; Cellvizio clearance; FDA’s new pilot program aims for more transparency
Category: Science & Medicine
Duration: 00:07:21
Publish Date: 2018-03-20 07:00:00
Description:

March 20, 2018

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com 

1:05 U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC) https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_grants_priority_review_for_a_supplemental_new_drug_application_snda_for_xtandi_enzalutamide_in_non_metastatic_castration_resistant_prostate_cancer_crpc

2:28 Cook Medical’s Cellvizio® Receives Further FDA 510(k) Clearance https://www.businesswire.com/news/home/20180319006147/en/Cook-Medical%E2%80%99s-Cellvizio%C2%AE-Receives-FDA-510-Clearance 

3:40 FDA’s new pilot program aims for more transparency about new drug approvals https://blogs.fda.gov/fdavoice/index.php/2018/03/fdas-new-pilot-program-aims-for-more-transparency-about-new-drug-approvals/ 

Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com.

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Total Play: 0